Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting [Yahoo! Finance]
Artivion, Inc. (AORT)
Company Research
Source: Yahoo! Finance
72% Reduction in All-Cause Mortality and 52% Reduction in Primary Major MAEs when Compared to Current Standard of Care Hemi-arch Procedure ATLANTA Jan. 29, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of results from the AMDS PERSEVERE clinical trial in a Late-Breaking Science presentation at the 60 th Annual Meeting of the Society of Thoracic Surgeons in San Antonio, Texas . The data presented analyzed clinical outcomes across the full 93 study participant IDE cohort at 30-days following AMDS implantation. Dr. Wilson Szeto , Chief of Cardiovascular Surgery at Penn Presbyterian Medical Center, presented the data from the PERSEVERE US IDE trial as a late-breaking abstract titled, Results of a Novel Aortic Arch Hybrid Prosthesis for Open Repair of Acute DeBakey Type I Dissection with Malperfusion: 30-day Results from the PERSEVERE Study Data from the trial demonstrate s
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual MeetingPR Newswire
- Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial ResultsPR Newswire
- Artivion's (NYSE:AORT) investors will be pleased with their notable 43% return over the last year [Yahoo! Finance]Yahoo! Finance
- Is Artivion (AORT) Outperforming Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Artivion, Inc. (NYSE: AORT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.MarketBeat
AORT
Earnings
- 2/15/24 - Beat
AORT
Sec Filings
- 4/1/24 - Form ARS
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form DEF
- AORT's page on the SEC website